
    
      This study consisted of 3 study visits (Screening/Baseline, Week 4, and Week 12). Eligible
      patients self-administered the study medication (AZARGAÂ® Eye Drops), adjunct to their current
      prostaglandin monotherapy for 3 months.
    
  